SCHEMBL5324571

SCHEMBL5324571

NCCCCCC(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 12/20 0.80
▸ HDAC2 Q92769 10/20 0.80
▸ HDAC3 O15379 10/20 0.80
▸ HDAC6 Q9UBN7 9/20 0.80
▸ HDAC10 Q969S8 9/20 0.80
▸ HDAC9 Q9UKV0 8/20 0.80
▸ HDAC8 Q9BY41 7/20 0.80
▸ HDAC4 P56524 6/20 0.80
▸ HDAC7 Q8WUI4 6/20 0.80
▸ HDAC11 Q96DB2 6/20 0.80
▸ HDAC5 Q9UQL6 6/20 0.80
▸ NCOR2 Q9Y618 1/20 0.65
▸ ELOVL1 Q9BW60 1/20 0.63
▸ PARP1 P09874 1/20 0.61
▸ MAPT P10636 1/20 0.60
▸ LMNA P02545 1/20 0.60
▸ MAPK1 P28482 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24359340 1.00 HDAC1 (0.80) HDAC1HDAC2HDAC3HDAC6HDAC10
SCHEMBL11479812 0.88 HDAC1 (0.80) HDAC1HDAC2HDAC3HDAC6HDAC10
SCHEMBL30444296 0.88 HDAC1 (0.80) HDAC1HDAC2HDAC3HDAC6HDAC10
SCHEMBL35210420 0.88 HDAC1 (1.00) HDAC1HDAC2HDAC3HDAC6HDAC10
SCHEMBL17107157 0.88 HDAC1 (0.80) HDAC1HDAC2HDAC3HDAC6HDAC10
SCHEMBL17107235 0.86 HDAC1 (0.77) HDAC1HDAC2HDAC3HDAC6HDAC10
SCHEMBL5849033 0.86 MAPK1 (0.79) HDAC1HDAC2HDAC3HDAC6HDAC10
SCHEMBL24359606 0.85 HDAC1 (0.76) HDAC1HDAC2HDAC3HDAC6HDAC10
SCHEMBL24359499 0.84 HDAC1 (0.74) HDAC1HDAC2HDAC3HDAC6HDAC10
SCHEMBL7369128 0.84 HDAC1 (1.00) HDAC1HDAC2HDAC3HDAC6HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007143822-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-21 — — WO disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 — — US disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 — — US disclosed
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS METHYLGENE INC. (CA) 2007-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293530-A1 SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HAT1 HDAC1 1/4885HDAC2 6/4885HDAC3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback